Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 3/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 6/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13754134 | 0.80 | PIN1 (0.40) | ADRB2ADRB1ADRB3ALDH1A1LMNA | |
| SCHEMBL13754166 | 0.80 | MEN1 (0.47) | ALDH1A1LMNAMAPK1SMN1; SMN2MEN1 | |
| SCHEMBL13754136 | 0.79 | ESRRG (0.45) | ALDH1A1LMNAMEN1KMT2ATDP1 | |
| SCHEMBL13754138 | 0.78 | NR1H4 (0.52) | ALDH1A1LMNAMAPK1SMN1; SMN2MEN1 | |
| SCHEMBL6871792 | 0.78 | ACACB (0.37) | ALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL13754143 | 0.77 | NR1H4 (0.51) | TAS1R3TAS1R1 | |
| SCHEMBL4445520 | 0.75 | MEN1 (0.41) | ALDH1A1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL13754161 | 0.75 | TAS1R3 (0.51) | ADRB2ADRB1ADRB3TAS1R3TAS1R1 | |
| SCHEMBL13754141 | 0.74 | NR4A2 (0.44) | ADRB2ADRB1ADRB3TAS1R3TAS1R1 | |
| SCHEMBL13754169 | 0.74 | NR1H4 (0.45) | LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572938-B2 | Precursors for ketones and aldehydes | GIVAUDAN SA (CH) | 2009-08-11 | — | — | US | disclosed |
| US-7572938-B2 | Precursors for ketones and aldehydes | GIVAUDAN SA (CH) | 2009-08-11 | — | — | US | disclosed |
| US-7572938-B2 | Precursors for ketones and aldehydes | GIVAUDAN SA (CH) | 2009-08-11 | — | — | US | disclosed |
| US-20040171516-A1 | Precursors for ketones and aldehydes | GIVAUDAN SA (CH) | 2004-09-02 | — | — | US | disclosed |
| EP-1262473-A1 | Precursors for fragrant ketones and fragrant aldehydes | Givaudan SA (CH) | 2002-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171516-A1 | Precursors for ketones and aldehydes | PDK3, PDK4, AKR1C4 | ADRB2 1790/4885ADRB1 1752/4885ADRB3 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.